Nova Eye Medical Ltd · ASX:EYE

Nova Eye Medical — Evans & Partners Small Cap Healthcare Conference 2023

15 slides from Nova Eye Medical's conference presentation, Sep 12, 2023

  1. Slide 1: Addressing the Leading Causes of Blindness

    For personal use only Addressing the Leading Causes of Blindness Nova Eye Medical Limited (ASX:EYE) Evans & Partners Small Cap Healthcare Conference September 2023 nova-eye.com | 1

  2. Slide 2: Disclaimer

    Disclaimer This presentation has been prepared by Nova Eye Medical Limited (ASX: EYE). While the information in this presentation has been prepared in good faith and with reasonable care, no For personal use only representation or warranty, express or implied, is made as to the accuracy, adequacy or

  3. Slide 3: Business Snapshot

    Business Snapshot Nova Eye Medical leads the way in interventional treatment solutions for glaucoma and age-related macular degeneration (AMD), the leading causes of blindness in the developed world. For personal use only Nova Eye Medical, Glaucoma AlphaRET, AMD Develop, market and sell comprehensiv

  4. Slide 4: Company Overview

    Company Overview Capital Structure Share Price Chart $0.35 ASX Code EYE 6,000,000 For personal use only Share Price (at 7 September 2023) $0.195 5,000,000 $0.30 Shares on Issue 190 M 4,000,000 $0.25 Unlisted Options 3.35 M 3,000,000 Market Capitalisation $37.16 M $0.20 2,000,000 Cash $7.54M $0.15 1,

  5. Slide 5: FY23 Achievements

    FY23 Achievements Strong Financial Results with Record Global Sales For personal use only Record Substantial lift in global sales gross margin to Cash on hand US$11.3m 73% A$7.4m for the glaucoma surgical compared to 60% at 30 June 2023 to devices segment in the first half FY23 support growth nova-e

  6. Slide 6: Glaucoma, Disease Overview

    GLAUCOMA, DISEASE OVERVIEW For personal use only • Glaucoma is the leading cause of blindness in the developed world. • Progressive, irreversible eye disease that causes vision loss due to optic nerve damage. • Elevated intraocular pressure (IOP) is the most significant risk factor for the developme

  7. Slide 7: iTrack Advance canaloplasty device

    7 For personal use only • New iTrack™ Advance consumable MIGS device is redefining the treatment of glaucoma in its early stages. • Canaloplasty offers a stent-free, tissue-preserving surgical treatment for glaucoma. • Enhanced version of our original iTrack™ microcatheter, which was first brought t

  8. Slide 8: Our Glaucoma Opportunity

    Our Glaucoma opportunity • The glaucoma consumable surgical devices market For personal use only is the fastest growing segment of the ophthalmic market. 156.2 million • The aging global population drives prevalence, People worldwide with Glaucoma1 representing a significant opportunity for our glob

  9. Slide 9: USA Sales Growth Plan

    USA Sales Growth Plan, A Active Accounts, Glaucoma (x200) B Inactive Accounts, Glaucoma (x300) Current Sales Growth iTrack™ Advance C New Accounts, Glaucoma (x900) 32% reported for 3 months to 31 July Active Accounts, Glaucoma | x200 surgeons For personal use only A Successfully transitioned existin

  10. Slide 10: USA Sales Update

    USA SALES UPDATE For personal use only Following the USA launch of iTrack™ Advance at the ASCRS meeting in May 2023, 1 total USA sales in the three (3) months to 31 July 2023 were approx. US$2.2 million, up 32% on the pcp and sales growth since then is on target. 2 Solid sales growth in the USA is b

  11. Slide 11: Clinical Data Update: Real-World Registry Data

    Clinical Data Update Real-World Registry Data Reinforces Safety and Efficacy of iTrackTM Summary of the Real-World Registry so far: Continued to invest in clinical data program to support market For personal use only development and market access • 367 patients of a broad range of ethnicities. initi

  12. Slide 12: AlphaRET for Retinal Disease

    AlphaRET for RETINAL DISEASE For personal use only • Age-related macular degeneration (AMD) is the leading cause of blindness in industrialised countries in people over the age of 50 years. • Late-stage Wet AMD market is currently the only market served (drug 2RT® is a proprietary, world-first thera

  13. Slide 13: Overview of AMD Market

    Overview of AMD Market For personal use only Intermediate stage disease – AlphaRET Late stage macular degeneration (Treats underlying causes of AMD.) Wet Dry Intermediate Intermediate AMD (CNV) AMD (GA) AMD AMD Choroidal Geographic Atrophy Neovascularization 54 million 14 million 55 million people w

  14. Slide 14: Nova Eye Group Outlook

    Nova Eye Group Outlook Sales of new iTrack™ Advance in the USA are driving and are expected to drive, significant sales growth for the Company’s For personal use only glaucoma surgical device segment in the 2024 financial year and beyond. Operating expenditure will increase to support the expansion

  15. Slide 15: Contact details

    For personal use only Tom Spurling Kate Hunt Mark Flynn Managing Director Chief Commercial Officer Investor Relations +61 8 8362 0193 +61 404 080 679 +61 416 068 733 [email protected] [email protected] [email protected] nova-eye.com | 15

Nova Eye Medical — Evans & Partners Small Cap Healthcare Conference 2023 on 6ix